Alcyone trial myeloma
WebDec 10, 2024 · ALCYONE was a multicentre, randomised, open-label, active-controlled, phase 3 trial that enrolled patients between Feb 9, 2015, and July 14, 2016, at 162 sites … WebDec 13, 2024 · The first trial was conducted predominantly in Europe, and it worked on the basis that bortezomib, melphalan, and prednisone was an accepted regimen in European circles for treatment of myeloma in older individuals, and to which the trial then looked at VMP [ bortezomib, melphalan, prednisone] versus VMP [bortezomib, melphalan, …
Alcyone trial myeloma
Did you know?
WebOct 11, 2024 · Finally, Kumar highlight results from the phase 3 randomized ALCYONE trial (NCT02195479), which explored daratumumab, bortezomib, melphalan, and prednisone (D-VMP) in newly diagnosed patients with multiple myeloma who were ineligible for SCT. Based on the published results, the regimen significantly improved PFS after 3 years of … WebJan 11, 2024 · Methods: ALCYONE was a multicentre, randomised, open-label, active-controlled, phase 3 trial that enrolled patients between Feb 9, 2015, and July 14, 2016, at …
WebAbout the ALCYONE Trial 1 The randomized, open-label, multicenter Phase 3 ALCYONE (MMY3007) study enrolled 706 newly diagnosed patients with multiple myeloma who were ineligible for high-dose chemotherapy with ASCT. The median age was 71 years (range: 40-93). Patients were randomized to receive up to nine cycles of either DARZALEX-VMP or … WebDec 9, 2024 · The early experience with quadruplet regimens in NDMM was evaluated in 2 randomized phase 3 trials: ALCYONE and CASSIOPEIA. 10, 11 The ALCYONE study evaluated bortezomib-melphalan-prednisone with or without daratumumab in transplant-ineligible patients with NDMM.
WebDec 4, 2024 · The ALCYONE study evaluated VMP with or without daratumumab in transplant-ineligible NDMM patients (median age, 71 years). 1,2 Patients treated with daratumumab achieved a deeper response and had improved progression-free survival (PFS) compared with patients who were treated with VMP alone. WebJul 1, 2024 · The Alcyone trial showed that the addition of daratumumab to the standard combination of bortezomib, melphalan, and prednisone plus maintenance treatment with daratumumab not only dramatically improved PFS (median, 36.4 vs 19.3 months; HR, 0.42) but also significantly improved OS, with a median follow-up of only 40 months (36-month …
WebThe approval was based on results of the phase 3 ALCYONE trial in which the addition of daratumumab to bortezomib, melphalan and prednisone significantly prolonged median progression-free survival (PFS) relative to bortezomib, melphalan and prednisone alone (primary endpoint).
WebALCYONE. (NCT02195479) A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan … healing church beirutWebAbout the ALCYONE Trial1. The randomized, open-label, multicenter Phase 3 ALCYONE (MMY3007) study enrolled 706 newly diagnosed patients with multiple myeloma who … healing chub rubWebApr 3, 2024 · MAIA and ALCYONE: follow-up of daratumumab in multiple myeloma ... Multiple Myeloma trial highlights: ARROW, OPTIMISMM & ALCYONE. Mohamad … healing chronic pancreatitisWebJul 1, 2024 · In ALCYONE, after longer follow-up, an overall survival (OS) benefit was observed; adding DARA to bortezomib, melphalan, and prednisone significantly reduced … healing church bloodborneWebMar 31, 2024 · Conclusion: D-Rd compared with Rd was associated with faster and sustained clinically meaningful improvements in PROs, including pain, in transplant-ineligible patients with newly diagnosed multiple myeloma regardless of age, baseline ECOG status, or depth of treatment response. Trial registration: ClinicalTrials.gov NCT02252172. healing churches near meWebSep 26, 2024 · BOSTON – Response rates observed with subcutaneous daratumumab–based combinations in the PLEIADES trial were similar to rates observed with intravenous daratumumab–based combinations in three other trials. healing churchWebJun 18, 2024 · Multiple myeloma (MM) has a worldwide incidence of 1–5/100,000/year. Outcomes have improved significantly in recent years following incorporation of immunomodulatory drugs and proteasome inhibitors into standard-of-care regimes. MM is profoundly immunosuppressive, enabling immune evasion, proliferation and disease … healing church of rhode island